ClinicalTrials.gg
CompletedNCT07199439PMCFStypcelUpdated Sep 30, 2025

Post-market Clinical Follow-up Plan of StypCel™ Absorbable Hemostat

An observational study in Neurosurgery, sponsored by Medprin Regenerative Medical Technologies Co., Ltd.. Completed at 1 site in Latvia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Medprin Regenerative Medical Technologies Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
108
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a post-market clinical follow-up (PMCF) plan for the StypCel™ Absorbable Hemostat, a medical device used to control bleeding during neurosurgery. The study include 108 patients . The aim of the study is to furtherly assess the safety and performance of the device under the real-word setting

Read the detailed description

The StypCel™ Absorbable Hemostat is designed to control bleeding during neurosurgical procedures. This PMCF study is an observational, multicenter study included 108 patients .Primary goal is to evaluate the device's ability to achieve hemostasis within 5 minutes during surgery. Secondary objectives include monitoring the rate of intracranial infections and other serious adverse events over 6 months. Data from the study will be collected at two-time points: 10 days and 180 days after the surgery, with follow-up assessments to monitor any delayed complications.

These summaries are written in plain language, ensuring they are accessible to non-specialists while still providing essential information about the study's objectives, methodology, and expected outcomes.

02

Conditions studied

  • Neurosurgery

Browse trials for

Keywords

  • bleeding
03

In context

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

This study's enrollment of 108 is below the median of 215 across 397 observational studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Medprin Regenerative Medical Technologies Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adult patients undergoing neurosurgical procedures where the StypCel™ Absorbable Hemostat is used to control intraoperative bleeding. The population is drawn from multiple hospitals specializing in neurosurgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18-75 years of age
  • Patients requiring a hemostat device during neurosurgery.
  • Patients and/or guardians agree to take part in the PMCF study and sign the Form.

Exclusion criteria

Exclusion Criteria:

  • Patients with bone defects, because it may interfere with callus formation and a possibility of cyst formation.
  • StypCel™ should not be used in the control of hemorrhage from large arteries. StypCel™ should not be used as an anti-adhesion product.
  • StypCel™ should not be used on the surface of non-hemorrhagic serous effusion, because in addition to the whole blood, the fluid does not react with the absorbable hemostat with satisfied hemostatic effect.
  • StypCel™ is to be avoided in surgical cases requiring stuffing and packing (as is sometimes medically necessary). It may only be used in such a situation if the surgeon completely removes the device after hemostasis is achieved.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
108 participants (actual)
Patient registry
No

Groups and cohorts

  • StypCel™ Neurosurgery Patients

    This cohort includes patients undergoing neurosurgery where the StypCel™ Absorbable Hemostat is used to achieve hemostasis. The study will observe and document the effectiveness of the device in controlling bleeding during the surgery and track any subsequent complications, including infections and other adverse events, over a 6- month follow-up period

06

What researchers measure

Primary outcomes

  1. Time to Hemostasis within 5 mins

    The primary outcome is the time taken to achieve complete hemostasis at the surgical site after applying the StypCel™ Absorbable Hemostat during neurosurgery.

    Time frame: during surgery (typically within 5 minutes)

  2. Time to Hemostasis

    Time to Hemostasis within 5 minutes

    Time frame: During surgery

07

Study locations

1 site
  • Riga's East Clinical University Hospital Riga, Latvia
    Riga, Latvia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Apr 2023, 0 months.

Of 158 observational studies under Hemorrhage, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 74. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Apr 23, 2023
Primary completionActual
Apr 25, 2023
CompletionActual
Oct 15, 2024
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07199439
Collaborators
MDCECRO LLC
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Apr 23, 2023
Primary completion
Apr 25, 2023
Completion
Oct 15, 2024
Last update
Sep 30, 2025

Study contacts

Kaspars Auslands, Dr.
principal investigator · Riga's East Clinical University Hospital Riga, Latvia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion